Electroporation of epicardial autonomic ganglia: Safety and efficacy in medium-term canine models.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
04 2019
Historique:
received: 20 11 2018
revised: 19 01 2019
accepted: 19 01 2019
pubmed: 27 1 2019
medline: 21 7 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Endocardial radiofrequency ablation of epicardial ganglionic plexus (GP) for atrial fibrillation (AF) is complicated by myocardial damage. We hypothesized that an epicardial approach with a novel nitinol catheter system capable of causing irreversible electroporation (IRE) with direct current (DC) could selectively and permanently destroy GP without collateral myocardial injury. Acute studies and medium-term terminal studies (mean survival, 1137 days) were performed with seven dogs. In the acute studies, DC was used to target epicardial GP within the transverse sinus, oblique sinus, vein of Marshall, and right periaortic space. Successful electroporation was defined as the presence of ablative lesions in the GP without collateral myocardial damage. A four-point integer system was used to classify histologic changes in tissue harvested from the ablation sites. Atrial effective refractory period (AERP) was measured during the acute and medium-term studies. For six dogs in the medium-term studies, the postablation period was uneventful without complications. Lesions were successfully created at 20 of 21 sites (95.2%) with more than minimal myocardial damage in one dog. An increase in AERP occurred in both atria during the acute studies but was maintained only in the right atrium at medium-term follow-up (5032 milliseconds). No dog had damage to the esophagus, adjacent great arteries, or pulmonary veins. This proof-of-concept study suggests that safe, effective, and selective epicardial ablation of GP can be performed with DC by IRE with minimal collateral myocardial damage.

Sections du résumé

BACKGROUND
Endocardial radiofrequency ablation of epicardial ganglionic plexus (GP) for atrial fibrillation (AF) is complicated by myocardial damage.
OBJECTIVES
We hypothesized that an epicardial approach with a novel nitinol catheter system capable of causing irreversible electroporation (IRE) with direct current (DC) could selectively and permanently destroy GP without collateral myocardial injury.
METHODS
Acute studies and medium-term terminal studies (mean survival, 1137 days) were performed with seven dogs. In the acute studies, DC was used to target epicardial GP within the transverse sinus, oblique sinus, vein of Marshall, and right periaortic space. Successful electroporation was defined as the presence of ablative lesions in the GP without collateral myocardial damage. A four-point integer system was used to classify histologic changes in tissue harvested from the ablation sites. Atrial effective refractory period (AERP) was measured during the acute and medium-term studies.
RESULTS
For six dogs in the medium-term studies, the postablation period was uneventful without complications. Lesions were successfully created at 20 of 21 sites (95.2%) with more than minimal myocardial damage in one dog. An increase in AERP occurred in both atria during the acute studies but was maintained only in the right atrium at medium-term follow-up (5032 milliseconds). No dog had damage to the esophagus, adjacent great arteries, or pulmonary veins.
CONCLUSIONS
This proof-of-concept study suggests that safe, effective, and selective epicardial ablation of GP can be performed with DC by IRE with minimal collateral myocardial damage.

Identifiants

pubmed: 30680839
doi: 10.1111/jce.13860
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

607-615

Subventions

Organisme : Commercialization Fund Programme (Enterprise Ireland)/Minnesota Partnership for Biotechnology and Medical Genomics (University of Minnesota and Mayo Clinic)
Pays : International

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Deepak Padmanabhan (D)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Niyada Naksuk (N)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Ammar K Killu (AK)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Suraj Kapa (S)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Chance Witt (C)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Alan Sugrue (A)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Christopher V DeSimone (CV)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Malini Madhavan (M)

Department of Cardiovascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

J R de Groot (JR)

Heart Center, Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Barry O'Brien (B)

Biomedical engineering, National University of Ireland, Galway, Ireland.

Tadhg Rabbette (T)

Biomedical engineering, National University of Ireland, Galway, Ireland.

Kenneth Coffey (K)

Biomedical engineering, National University of Ireland, Galway, Ireland.

Samuel J Asirvatham (SJ)

Division of Pediatric Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH